QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Extensive GLP-1 Study Program

 Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today unveiled a comprehensive planned applied research program to thoroughly evaluate DehydraTECH for the improved delivery of GLP-1 drugs, designed to support prospective commercial partnering with global pharmaceutical companies. In a recent human pilot study with seven volunteers, Lexaria demonstrated superior pharmacokinetic (“PK”) oral delivery performance of the DehydraTECH-enhanced glucagon-like peptide-1 (“GLP-1”) drug semaglutide, available commercially in the branded product Rybelsus(R). The positive results were sufficient to encourage a much more thorough and expanded investigation. The objective of the new planned studies, as detailed in the announcement, is to help determine the commercial applicability of DehydraTECH to at least three GLP-1 drugs (semaglutide, liraglutide and tirzepatide), which together produced billions in revenue to their owners as reported in recent financial statements.

To view the full press release, visit https://ibn.fm/MuCaC

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 38 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About QualityStocks

QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer

QualityStocks
Scottsdale, AZ
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

QualityStocks is powered by IBN

QualityStocksNewsBreaks – FingerMotion Inc. (NASDAQ: FNGR) Releases Third-Quarter 2024 Financial Report

 FingerMotion (NASDAQ: FNGR), a mobile services and data company, is reporting on its financial results for the third quarter of fiscal 2024, the period ended Nov. 30, 2023. Numbers to note from the report include quarterly revenue of $6.14 million, which includes the company’s SMS & MMS, Telecommunications Products & Services businesses as well as Big Data, totaled $5.26 million, or 46% decrease, compared to Q3 2023; a quarterly decrease in Telecommunications Products & Services business revenue of $4.22 million or 41% compared to Q3 2023; quarterly Big Data revenue of $.01 million compared to $.19 million in Q3 2023; quarterly SMS & MMS business revenue of $.01 million compared to $.87 million in Q3 2023; quarterly cost of revenue of $5.50 million, which was down 48%, or $5.04 million, from Q3 2023; a gross profit of $.64 million, down $.22 million, or 26%, when compared to Q3 2023, with a quarterly loss of $1.94 million, which was a decrease of $0.58 million compared to Q3 2023. The report also noted a basic and diluted loss per share of $0.04 versus a loss per share of $0.06 for Q3 2023. The reported also noted that as of Nov. 30, 2023, the company had $1,934,565 in cash and cash equivalents, a working capital surplus of $12,510,848 and a positive shareholders equity of $12,636,828 with assets totaling $17.57 million, current liabilities totaling $4.92 million and total liabilities reaching $4.92 million. “The numbers do not reflect the optimism that management sees going forward,” said FingerMotion CEO Martin Shen in the press release. “We were looking for positive cash flow from our diversification into new business segments by the end of the quarter but missed the cutoff. Exciting new business segments are underway in the current quarter that could improve revenues, margins, and get us close to our goal of profitability. We are building this business for the long term and innovate our way out of market challenges.”

To view the full press release, visit https://ibn.fm/rDVtg

About FingerMotion Inc.

FingerMotion is an evolving technology company with a core competency in mobile payment and recharge platform solutions in China. As the user base of its primary business continues to grow, the company is developing additional value-added technologies to market to its users. The vision of the company is to rapidly grow the user base through organic means and have this growth develop into an ecosystem of users with high engagement rates utilizing its innovative applications. Developing a highly engaged ecosystem of users would strategically position the company to onboard larger customer bases. FingerMotion eventually hopes to serve more than 1 billion users in the China market and eventually expand the model to other regional markets. For more information about the company, please visit www.FingerMotion.com.

NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

About QualityStocks

QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer

QualityStocks
Scottsdale, AZ
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

QualityStocks is powered by IBN

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Business Update, Milestones

 InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today outlined key accomplishments from 2023 and provided key strategic priorities for 2024. “In 2023, we experienced significant progress in both InMed’s pharmaceutical drug development and in BayMedica’s health and wellness initiatives. Our primary accomplishments throughout the year included a number of key milestones, such as the completion of a phase 2 clinical trial and the launch of two new preclinical programs targeting the treatment of Alzheimer’s disease and age-related macular degeneration (‘AMD’),” said Eric A. Adams, InMed president and CEO. “As we embark on 2024, we are placing increased emphasis on proprietary small molecule drug development candidates in our pharmaceutical pipeline with two exciting new programs addressing critical unmet medical needs. Firstly, INM-901 for the treatment of Alzheimer’s disease is showing promise via multiple mechanisms of action, including an increase in neuroprotection and an improvement in neuronal function via neuritogenesis. Secondly, INM-089 for the treatment of AMD appears to play a role in the preservation of retinal function, proactively protecting the retinal cells that are responsible for vision. Our focus on developing proprietary cannabinoid analogs over the past two years has started to pay dividends, evident in their utilization in these two new preclinical programs.”

To view the full press release, visit https://ibn.fm/hexgH

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. Together with its subsidiary, BayMedica, InMed has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. It is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About QualityStocks

QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer

QualityStocks
Scottsdale, AZ
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

QualityStocks is powered by IBN

QualityStocksNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Releases CEO Shareholder Message

 Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, has released a message for its shareholders from CEO Mark Dybul. In the message, Dybul provides an update about key developments the company experienced during 2023, including signing a definitive agreement to combine with the European-based, cutting-edge artificial-intelligence (“AI”) company GEDi Cube; GEDi Cube’s partnership with NVIDIA to expand its multiomic capabilities to multimodal; and consistently achieving “the holy grail of cancer research” in preclinical studies. The company has also scheduled a shareholder meeting on Jan. 25, 2024, to vote on matters related to the combination with GEDi Cube. In the message, Dybul also noted that 2024 has gotten off to a promising start, reporting that the company has been advised by GEDi Cube that its team has accelerated its multiomic health technology and is focused on pursuing key partnerships that will contribute to the commercialization of potential products and lay a solid foundation for a client base for rapid uptake when products become available. As a result, GEDi Cube has become a formal inception partner of NVIDIA. The message also stated that GEDI Cube has progressed its efforts with a three-phase workflow for its AI platform for biomarker discovery. The company has also made progress in advancing its cancer vaccine, RENB-DC11, toward studies in human, based on results obtained in experiments of pancreatic cancer in humanized mice.

“The structure envisioned for the combined company, and as outlined in the proxy, is a topco, for which I would serve as CEO, and two subsidiaries — Renovaro Bioscience and GEDi Cube, with the intention to change the name to Renovaro AI or another appropriate name,” said Renovaro BioSciencesCEO Mark Dybul in the shareholder message. “This approach is intended to allow each subsidiary to advance its cutting-edge technologies without introducing cultural and management challenges inherent in business combinations. However, as indicated, we have already begun planning for a multiplier effect at the intersection of the health tech and biotech platforms. This could lead to potentially numerous ‘AI clones’ and new therapies that could create the foundation for evergreen business opportunities. We firmly believe the winning combination of cutting-edge health tech and biotech offers an opportunity for an end-to-end approach to cancer — from early diagnosis and detection of recurrence to prediction of treatment effectiveness to the discovery of new therapies while advancing our existing therapeutic vaccine towards our vision for living a long, healthy life free from toxic chemotherapy.”

To view the message, visit https://ibn.fm/tEWIY

About Renovaro BioSciences Inc.

Renovaro BioSciences has developed advanced cell, gene and immunotherapy platforms designed to renew the body’s natural tumor-fighting capabilities against cancer and infectious diseases. For more information about the company, visit www.RenovaroBio.com.

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

About QualityStocks

QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer

QualityStocks
Scottsdale, AZ
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

QualityStocks is powered by IBN

QualityStocksNewsBreaks — Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF) (FSE: A0I0) Reports Significant Assay Results at Saskatchewan Project, Upgraded Results in Brazil Project

 Appia Rare Earths & Uranium (CSE: API) (OTCQX: APAAF) (FSE: A0I0), a publicly traded Canadian company in the rare earth element and uranium sectors, has announced initial geochemical assay results from its 2023 drilling program; the program was conducted on the Magnet Ridge Zone at Appia’s Alces Lake Project in northern Saskatchewan. According to the announcement, these significant findings “mark a pivotal milestone” in the company’s focus and commitment to advance exploration and development initiatives within the prolific Athabasca Basin area. Highlights of the report include returned assays of up to 1.57 wt.% (15,700 ppm) total rare earth oxides (“TREO”), with thickness and grades increasing to the south-southeast; mineralization intervals occurring from near surface to less than 85 meters depth; and multiple intervals in 23-MR-002 and 23-MR-003, extending downward in a westerly direction. The company also noted that it plans future exploration to continue in the west-southwest, extending downward into current intersections toward the mineralization at Magnet Ridge West. “The 2023 Alces Lake exploration campaign completed a successful season of prospecting, channel sampling and diamond drilling across the entire large property,” said Appia Rare Earths & Uranium lead geologist Kahlen Branning in the press release. “Specifically, here at Magnet Ridge, our team was able to delineate the SSE-most extent of the Magnet Ridge mineralization. Our prospecting team has uncovered a multitude of new, potential drill targets on the property that necessitate further detailed exploration, many of these display anomalous radioactive counts, from 5,000 counts per second (cps) to 40,000 cps. These new zones match our original hypothesis regarding the location of low-to-high-grade mineralization along the main regional shear zone and within the fold nose/hinge zone area of a large regional fold structure.”

In addition, the company also announced a substantial increase in the total weighted average grade of drill hole PCH-RC-063 at its PCH Ionic Adsorption Clay project, which is located in Goias, Brazil. The company had reported on the drill hole in October 2023. The new announcement noted that the reverse circulation (“RC”) PCH-RC-063 drill hole exceeded multiple intervals limits of detection (“LOD”), which prompted a reanalysis of the drilling results using methods designed for very high-grade samples, which was conducted by SGS Geosl Labs. The updated assays reveal a significant 42.2% increase in TREO and a notable 9.2% increase in magnet rare earth oxides (“MREO”). “These assays not only validate the extraordinary results of the PCH-RC-063 drill hole but also underscore the substantial high-grade potential mineralization in the SW Extension Zone,” said Appia Rare Earths & Uranium CEO Tom Drivas in the press release. “We are excited about the possibilities revealed by these findings and advancing additional exploration and development efforts to fully tap into the promising potential of this high-grade zone.”

To view the full press releases, visit https://ibn.fm/KalHY and https://ibn.fm/paxPu

About Appia Rare Earths & Uranium Corp.

Appia is a publicly traded Canadian company in the rare earth element and uranium sectors. The company is currently focusing on delineating high-grade, critical rare earth elements and gallium on the Alces Lake property, as well as exploring for high-grade uranium in the prolific Athabasca Basin on its Otherside, Loranger, North Wollaston and Eastside properties. The company holds the surface rights to exploration for 113,837.15 hectares (281,297.72 acres) in Saskatchewan. The company also has a 100% interest in 13,008 hectares (32,143 acres), with rare earth element and uranium deposits over five mineralized zones in the Elliot Lake Camp, Ontario. Lastly, the company holds the right to acquire up to a 70% interest in the PCH Project, which is 40,963.18 hectares in size and located within the Goiás state of Brazil. The company successfully added 23,412.11 hectares to the PCH project, bringing the overall project size to 40,963.18 hectares. For more information about the company, please visit www.AppiaREU.com.

NOTE TO INVESTORS: The latest news and updates relating to APAAF are available in the company’s newsroom at https://ibn.fm/APAAF

About QualityStocks

QualityStocks (“QS”) is a specialized communications platform with a focus on private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, QS is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, QS brings its clients unparalleled recognition and brand awareness. QS is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-published: https://www.QualityStocks.com/Disclaimer

QualityStocks
Scottsdale, AZ
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

QualityStocks is powered by IBN